about
Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteinsRGS9 proteins facilitate acute tolerance to mu-opioid effectsEffector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNSRGS-Rz and RGS9-2 proteins control mu-opioid receptor desensitisation in CNS: the role of activated Galphaz subunitsActivation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitizationBehavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia.Myr+-Gi2 alpha and Go alpha subunits restore the efficacy of opioids, clonidine and neurotensin giving rise to antinociception in G-protein knock-down mice.The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons.Calcium/calmodulin-dependent protein kinase II supports morphine antinociceptive tolerance by phosphorylation of glycosylated phosducin-like protein.HINT1 protein cooperates with cannabinoid 1 receptor to negatively regulate glutamate NMDA receptor activity.Opiates as antidepressants.Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance.The plasticity of the association between mu-opioid receptor and glutamate ionotropic receptor N in opioid analgesic tolerance and neuropathic pain.In vivo modulation of G proteins and opioid receptor function by antisense oligodeoxynucleotides.The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9.The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.HINT1 protein: a new therapeutic target to enhance opioid antinociception and block mechanical allodynia.NO-released zinc supports the simultaneous binding of Raf-1 and PKCγ cysteine-rich domains to HINT1 protein at the mu-opioid receptor.G-receptor antagonists increased the activating effect of mastoparan on low Km GTPase of mouse PAG.Antibodies and antisense oligodeoxynucleotides to mu-opioid receptors, selectively block the effects of mu-opioid agonists on intestinal transit and permeability in mice.Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate.The σ1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control.RGSZ2 binds to the neural nitric oxide synthase PDZ domain to regulate mu-opioid receptor-mediated potentiation of the N-methyl-D-aspartate receptor-calmodulin-dependent protein kinase II pathway.Administration of myr(+)-G(i2)alpha subunits prevents acute tolerance (tachyphylaxis) to mu-opioid effects in mice.Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia.Intrathecal pertussis toxin attenuates the morphine withdrawal syndrome in normal but not in arthritic rats.Endogenous opioid peptides: comparative evaluation of their receptor affinities in the mouse brain.Sumoylated RGS-Rz proteins act as scaffolds for Mu-opioid receptors and G-protein complexes in mouse brain.Mastoparan reduces the supraspinal analgesia mediated by mu/delta-opioid receptors in mice.Antibodies raised against the N-terminal sequence of delta opioid receptors blocked delta-mediated supraspinal antinociception in mice.NMDAR-nNOS generated zinc recruits PKCgamma to the HINT1-RGS17 complex bound to the C terminus of Mu-opioid receptors.Intracerebroventricular N-ethylmaleimide differentially reduces supraspinal opioid analgesia in mice.The GBeta5 subunit that associates with the R7 subfamily of RGS proteins regulates mu-opioid effects.Brain-specific Galphaz interacts with Src tyrosine kinase to regulate Mu-opioid receptor-NMDAR signaling pathway.Detecting zinc release induced by mu-opioid receptor agonists in brain slices.The delta2-opioid receptor subtype stimulates phosphoinositide metabolism in mouse periaqueductal gray matter.Influence of Gz and Gi2 transducer proteins in the affinity of opioid agonists to mu receptors.Stimulation of mu- and delta-opioid receptors enhances phosphoinositide metabolism in mouse spinal cord: evidence for subtypes of delta-receptors.Dynorphin B-29: chemical synthesis and pharmacological properties in opioid systems in vitro.
P50
Q21223665-A1981DB7-D0FD-4889-9F33-2889AAF0D4A8Q28201477-6B9F4E56-2B48-42E4-89D9-DEE2922B1727Q28245135-7938FB05-C249-4815-A7A8-6B01B09705C1Q28299855-8D1EDFB1-5A7D-476D-93E5-14E782C4C624Q28301079-446126EF-974E-4771-A089-1986BA155F82Q30458391-ECA5FC82-9629-4AF5-90D2-57C2F32FC5C3Q30828627-CD76C5CA-D06F-4AE7-97B3-3EA3C5193396Q34659000-38746334-205F-47F4-AF93-88699C99DA79Q34682536-D2C9F389-9A75-436F-87FC-3A0E47F02195Q34713973-03F9BF06-83CD-4829-9042-7D4311A1BA7AQ37364657-64E5446A-8648-4762-BBAE-C038D9CDE4A1Q37481972-99CEA90F-ADB7-4698-AA95-34508DD6CE76Q38037679-757120C1-CC3F-445D-B811-47FEB6CDA37CQ38090227-910D5EEE-92D7-4A2E-8767-3AC531CFAA01Q38318349-91991474-4CBC-4C79-B1E1-018E2083414CQ38639528-8ADB4CF9-BA6B-42E4-B7A5-9E0EF5A242A0Q39904357-10B8366D-0A94-468F-B057-A57585B58A60Q41760609-C0AB4CF7-F854-4827-8C56-632CF3E2FA5AQ41879563-8C9B37DD-817B-4760-B492-B2B4C28B8D19Q42487021-3D503E55-CE93-49DD-8AA9-6149900EE447Q42751162-906E8804-AB45-484F-A2B4-B8E2EEFE6E60Q42872711-16056A91-AFDA-4BD0-AA7E-E5AE5A38E767Q43195386-947EE21B-D77F-41AC-B9CD-C3CEA58C4651Q43440389-74DEE4FA-9445-48DB-A628-C484712FA6D6Q43543026-D1DADCEA-5DE3-49CF-A8F0-4BA335CF43CDQ43557580-B1BCCC22-E37F-4686-9570-77434D3FFD5FQ44271378-ED284BB4-C725-48F6-9E54-3F1060B30D12Q44330040-EDD7067A-EEE4-43A9-BF02-25B734FCF890Q44331639-8E80BD81-508D-4175-804C-4F6E9DE9DA57Q44336760-182AADFE-1061-49D2-873B-C027528E241AQ44338207-AAE18830-51F3-4ECC-A533-8963C62FC992Q44339601-5D9215E7-E449-4076-812B-159898F42C0FQ44341516-FBB4F216-6FC5-4F32-A374-DED1650C121DQ44341937-55BC4FD3-00F5-4699-8232-1E59BF8FF024Q44342677-113313DC-2617-4D15-B4A9-8147186172EAQ44347620-E8659D91-7BA5-4955-9B19-DC89E4C10F6BQ44348662-3F88F616-5E0A-407D-ACCC-A5064ED5EF2CQ44350218-585BE7BE-3288-4BE3-AC9D-CB537C8760F0Q44352070-DB952581-85BF-4DAC-919F-875F1754BD6FQ44352510-FED6E780-6940-4BE6-870F-3BF4B4E87182
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
P Sánchez-Blázquez
@ast
P Sánchez-Blázquez
@en
P Sánchez-Blázquez
@es
P Sánchez-Blázquez
@nl
type
label
P Sánchez-Blázquez
@ast
P Sánchez-Blázquez
@en
P Sánchez-Blázquez
@es
P Sánchez-Blázquez
@nl
prefLabel
P Sánchez-Blázquez
@ast
P Sánchez-Blázquez
@en
P Sánchez-Blázquez
@es
P Sánchez-Blázquez
@nl
P108
P31
P496
0000-0002-7211-4504